You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Suppliers and packagers for generic pharmaceutical drug: epinephrine bitartrate


✉ Email this page to a colleague

« Back to Dashboard


epinephrine bitartrate

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Baxter Hlthcare Corp EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE epinephrine bitartrate SOLUTION;INTRAVENOUS 218475 NDA Baxter Healthcare Corporation 0338-0006-20 20 BAG in 1 CARTON (0338-0006-20) / 250 mL in 1 BAG 2026-03-16
Baxter Hlthcare Corp EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE epinephrine bitartrate SOLUTION;INTRAVENOUS 218475 NDA Baxter Healthcare Corporation 0338-0024-20 20 BAG in 1 CARTON (0338-0024-20) / 250 mL in 1 BAG 2025-02-28
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for the Pharmaceutical Drug: Epinephrine Bitartrate

Last updated: July 28, 2025

Introduction

Epinephrine Bitartrate, also known as adrenaline, is a critical medication widely utilized in emergency medicine for anaphylaxis, cardiac arrest, and other life-threatening conditions. Its global demand necessitates a reliable supply chain comprising reputable manufacturers and suppliers. Understanding the landscape of Epinephrine Bitartrate suppliers aids pharmaceutical companies, healthcare providers, and regulatory authorities in ensuring drug availability, quality, and compliance with international standards.

Global Market Overview

The global market for epinephrine is highly concentrated, with several key players dominating production due to the molecule’s critical role in emergency medicine and its inclusion in numerous pharmaceutical formulations. The demand for injectable epinephrine, particularly autoinjectors, has surged driven by increased awareness and diagnosis of allergic conditions. Consequently, suppliers are continuously innovating to meet regulatory standards and supply chain challenges.

Major Suppliers and Manufacturers of Epinephrine Bitartrate

1. Pfizer Inc.

Overview: Pfizer is a leading pharmaceutical multinational with a dominant position in epinephrine manufacturing. Their flagship product, EpiPen, leverages epinephrine auto-injector technology. Pfizer manufactures bulk epinephrine for use in autoinjectors and other formulations.

Supply Capabilities: Pfizer maintains extensive manufacturing facilities adhering to cGMP (current Good Manufacturing Practice), ensuring high-quality epoxyphrine Bitartrate production. Their global distribution network guarantees drug availability in multiple markets.

Regulatory Status: Pfizer’s products are approved by regulatory agencies such as the FDA and EMA, facilitating widespread distribution.

2. NovaMed

Overview: NovaMed specializes in raw pharmaceutical ingredients, including epinephrine Bitartrate. Based in India, they serve both domestic and export markets, offering high-purity active ingredients.

Supply Capabilities: NovaMed supplies bulk epinephrine Bitartrate to pharmaceutical companies for formulation purposes. Their manufacturing facilities are compliant with WHO-GMP standards.

Markets: Focuses on Asia, Africa, and parts of Europe, providing cost-effective options for global OEMs.

3. Jiangsu Nhwa Pharmaceutical Co., Ltd.

Overview: A prominent Chinese pharmaceutical company, Nhwa produces a broad spectrum of injectable drugs, including epinephrine Bitartrate. Their offerings are recognized for compliance with international standards.

Supply Capabilities: Equipped with advanced synthesis and purification technologies, Nhwa supplies bulk active ingredients to international markets.

Regulatory Recognition: Their manufacturing plants are approved by Chinese authorities and hold certifications like ISO and WHO-GMP, facilitating export to regulated markets.

4. Teva Pharmaceutical Industries Ltd.

Overview: An Israel-based generic pharmaceutical giant, Teva supplies epinephrine Bitartrate both as an active pharmaceutical ingredient (API) and in finished dosage forms.

Supply Capabilities: Teva operates extensive manufacturing facilities with strict quality control protocols, ensuring consistent supply and high purity.

Global Reach: Their global distribution allows wide access to epinephrine products, notably in North America and Europe.

5. Shanghai Flordecai Pharmaceutical Co., Ltd.

Overview: A Chinese supplier focusing on sterile injectable APIs, including epinephrine Bitartrate, catering to both domestic and international markets.

Supply Capabilities: Known for cost-effective production with compliance to cGMP standards, their products are often used in large-scale pharmaceutical manufacturing.


Emerging and Niche Suppliers

In addition to the major players, several smaller or regional companies have entered the market, often offering specialized formulations or competitive pricing:

  • Hunan Ovi Pharmaceutical Technologies: Focuses on eco-friendly synthesis methods.
  • AstraZeneca: Occasionally supplies epinephrine-containing combination therapies and formulations.
  • Local Asian manufacturers: Often provide cost-efficient APIs to generic drug producers, particularly in India and China.

Regulatory and Quality Considerations

The credibility of suppliers hinges on adherence to strict quality standards such as:

  • cGMP compliance: Ensuring consistent quality in manufacturing processes.
  • WHO-GMP certification: Essential for exporters targeting emerging markets.
  • FDA/EMA approval: Critical for products distributed in US and European markets.
  • Third-party testing and validation: Suppliers often undergo rigorous testing to certify the purity, potency, and stability of epinephrine Bitartrate.

Supply Chain Challenges

Global supply chains face persistent challenges including:

  • Raw material shortages: Epinephrine synthesis depends on raw chemicals like catechol derivatives, susceptible to supply disruptions.
  • Regulatory hurdles: Variations in approval processes can delay market entry.
  • Manufacturing capacity constraints: High demand often strains existing production facilities.
  • Quality assurance: Ensuring consistent product quality amidst diverse manufacturing standards.

Strategic Procurement Insights

  • Diversification: Engaging multiple suppliers minimizes risks of shortages.
  • Quality focus: Prioritizing suppliers with verified regulatory approval and strong quality assurance processes.
  • Localization: Partnering with regional suppliers for faster distribution and reduced logistics costs.

Conclusion

The supply landscape for Epinephrine Bitartrate is characterized by a mix of global pharmaceutical giants and regional manufacturers, predominantly in North America, Europe, and Asia. Ensuring a stable, quality-assured supply involves understanding each supplier's regulatory standing, manufacturing capacity, and compliance practices. The current market trend emphasizes high-purity, GMP-compliant APIs, with increasing regulatory scrutiny propelling suppliers toward maintaining stringent quality standards.


Key Takeaways

  • Pfizer and Teva dominate the global supply of Epinephrine Bitartrate, with robust manufacturing and distribution infrastructures.
  • Regional manufacturers like NovaMed and Nhwa provide cost-effective API options, especially for emerging markets.
  • Ensuring compliance with international regulatory standards (cGMP, WHO-GMP, FDA, EMA) is critical in supplier selection.
  • Supply chain resilience requires diversification among suppliers to mitigate raw material shortages and regulatory delays.
  • Collaboration with suppliers possessing advanced quality assurance capabilities is essential for maintaining product integrity and regulatory compliance.

Frequently Asked Questions

1. What are the primary regulatory standards to look for in Epinephrine Bitartrate suppliers?
Manufacturers should adhere to cGMP, WHO-GMP, and hold approvals from agencies like the FDA or EMA to ensure quality, safety, and efficacy.

2. How can pharmaceutical companies verify the quality of Epinephrine Bitartrate from new suppliers?
Through certification documentation, third-party testing results, and audits of manufacturing facilities, along with reviewing regulatory approval status.

3. Are there regional differences in the quality standards of Epinephrine Bitartrate suppliers?
Yes. While many Asian manufacturers meet global standards due to international certification processes, variability exists; thus, verification of compliance is crucial.

4. What factors influence the choice of supplier for Epinephrine Bitartrate?
Quality standards, regulatory approval, manufacturing capacity, price, supply reliability, and delivery timelines are key considerations.

5. Is the global supply of Epinephrine Bitartrate sufficient to meet growing demand?
While leading producers maintain adequate capacity, supply shortages can occur due to raw material constraints, regulatory issues, or increased demand, necessitating strategic sourcing.


References

[1] U.S. Food and Drug Administration. (2022). Epinephrine Injection, USP. FDA Drug Database.
[2] European Medicines Agency. (2022). Japanese and Chinese manufacturers' GMP inspections. EMA Reports.
[3] MarketsandMarkets. (2023). Epinephrine Market by Formulation and Region.
[4] Pharmaceutical Technology. (2021). Global supply chain challenges for APIs.
[5] WHO. (2022). Good Manufacturing Practices for Pharmaceuticals. WHO-GMP Certification Guidelines.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.